Skip to main content
Pharmena S.A. logo

Pharmena S.A. — Investor Relations & Filings

Ticker · PHR ISIN · PLPHRMN00011 LEI · 259400RHT936BBKW0955 WAR Manufacturing
Open in API
Filings indexed 649 across all filing types
Latest filing 2022-05-27 AGM Information
Country PL Poland
Listing WAR PHR

About Pharmena S.A.

https://www.pharmena.eu/

Pharmena S.A. is a specialty healthcare company focused on the development and commercialization of innovative products based on its patented active ingredient, 1-MNA. This molecule is a naturally occurring metabolite of niacin (vitamin B3) that plays a crucial role in cellular metabolism. The company's technology leverages the ability of 1-MNA to optimize the levels of the coenzyme NAD+, which decline with age and are vital for cellular function and regeneration. The product portfolio includes specialized cosmeceuticals, such as the Dermena line for hair loss, and dietary supplements designed to address the effects of cellular aging.

Recent filings

Filing Released Lang Actions
PHARMENA Projekty uchwał na ZWZ w dniu 28 06 2022
AGM Information Classification · 98% confidence The document text consists entirely of resolutions ('Uchwała') passed by the 'Zwyczajne Walne Zgromadzenie' (Ordinary General Meeting) of 'PHARMENA' S.A. on June 28, 2022. These resolutions cover the approval of annual reports (financial and management reports for 2021), voting on director/supervisor absolutions, approving remuneration policies, and setting board member compensation. The core subject matter is the formal proceedings and decisions made during an Annual General Meeting (AGM). This directly aligns with the definition for AGM Information (AGM-R). Although it touches upon remuneration (DEF 14A) and report approvals (AR/IR), the document itself is the record of the meeting where these actions took place.
2022-05-27 Polish
PHARMENA_Ogłoszenie o zwołaniu ZWZ w dniu 28 06 2022
AGM Information Classification · 99% confidence The document is titled "Ogłoszenie o zwołaniu Zwyczajnego Walnego Zgromadzenia Spółki..." which translates to "Announcement of the convening of the Ordinary General Meeting of the Company...". It details the date, time, location, and a comprehensive agenda (Porządek obrad) for the meeting, including items related to approving financial statements for 2021 and voting on remuneration policies. This content directly corresponds to the purpose of an Annual General Meeting (AGM) notice. The specific category for AGM materials and notices is AGM-R.
2022-05-27 Polish
Zwołanie Zwyczajnego Walnego Zgromadzenia spółki Pharmena S.A. - Content (PL)
AGM Information Classification · 98% confidence The document text is in Polish and announces the convening of an 'Zwyczajnego Walnego Zgromadzenia' (Ordinary General Meeting) scheduled for June 28, 2022. It explicitly states that the Management Board is enclosing the announcement regarding the convening of this meeting, along with draft resolutions and other related documents. Since the document is an announcement about an upcoming shareholder meeting and includes related materials (draft resolutions), it strongly aligns with the purpose of an Annual General Meeting (AGM) related filing. The code AGM-R covers 'Presentations and materials shared during the Annual General Meeting (AGM)'. Given the short length and the nature of the announcement, AGM-R is the most appropriate classification.
2022-05-27 Polish
zawiadomienia KP EGP 2022_04_26.pdf
Major Shareholding Notification Classification · 99% confidence The document is a formal notification ('Zawiadomienie') submitted to the Polish Financial Supervision Authority ('KOMISJA NADZORU FINANSOWEGO') by individuals (Konrad Palka and Ewa Gębicka-Palka) regarding a change in their total shareholding in PHARMENA S.A. The text explicitly references Article 69 and Article 87 of the Polish Public Offering Act, which govern notifications of significant changes in ownership thresholds. The content details the exact number of shares and voting rights before and after the change, crossing the 5% threshold. This directly corresponds to the definition of a Major Shareholding Notification.
2022-04-26 Polish
Ujawnienie stanu posiadania - zwiększenie przez akcjonariusza udziału powyżej 5% w ogólnej liczby głosów. - Content (PL)
Major Shareholding Notification Classification · 99% confidence The document text is a formal notification in Polish, citing specific articles of Polish public offering law (art. 70 pkt. 1, art. 69 ust. 1 pkt. 2, etc.). The content explicitly details a change in shareholding percentage (from below 5% to 8.86%) resulting from a donation of shares to the spouse of the CEO (Konrad Palka). This type of filing, reporting changes in significant share ownership thresholds by insiders or related parties, directly corresponds to the definition of Major Shareholding Notification (MRQ). The document concludes with 'W załączeniu zawiadomienie' (Notification attached), but the core content is the notification itself, not an announcement of a separate report, thus MRQ is the most appropriate classification over RPA or RNS.
2022-04-26 Polish
zawiadomienie EGP 2022_04_26.pdf
Director's Dealing Classification · 100% confidence The document is titled "Powiadomienie o transakcji/transakcjach*, o którym mowa w art. 19 ust. 1 rozporządzenia MAR" (Notification of transaction(s) referred to in Article 19(1) of the MAR Regulation). It details a transaction involving shares of PHARMENA S.A. by an individual closely associated with a member of the Management Board (Konrad Palka). Specifically, it reports the receipt of a donation of 500,000 shares at a price of 6.56 PLN on 2022-04-25. This content directly corresponds to the reporting requirements for insider transactions by directors and executives, which is classified as Director's Dealing (DIRS) in the provided schema.
2022-04-26 Polish

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.